KemPharm, Inc. — Form 10-Q Summary
Issuer note: The filing identifies the registrant as KemPharm, Inc. (ticker KMPH), not Zevra Therapeutics, Inc. The reporting period ended September 30, 2021; the filing was signed November 10, 2021.
Business context and reporting period
KemPharm is a specialty pharmaceutical company developing prodrugs using its Ligand Activated Therapy technology. Its products include FDA-approved AZSTARYS for ADHD and APADAZ for acute pain; AZSTARYS was launched in the U.S. during Q3 2021 by partner Corium. Its pipeline includes KP484 and KP879 for ADHD and stimulant use disorder, and preclinical candidate KP1077 for idiopathic hypersomnia. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | $1.965 million | $26.068 million | $1.925 million and $10.922 million, respectively |
| Operating income (loss) | $(2.222) million | $10.571 million | $(1.213) million and $(2.395) million, respectively |
| Net loss | $(1.759) million | $(5.852) million | $(3.009) million and $(7.904) million, respectively |
| Net loss attributable to common stockholders | $(1.759) million | $(60.194) million | $(3.009) million and $(7.904) million, respectively |
| Operating cash flow | Not separately presented | $11.287 million | $(0.880) million |
- At September 30, 2021, cash and cash equivalents were $131.503 million, total current assets $134.630 million, current liabilities $3.698 million, total liabilities $5.449 million, and stockholders’ equity $131.737 million.
- The company reported no convertible notes outstanding after repaying its remaining facility debt in February 2021. Operating lease liabilities totaled $1.673 million.
- Nine-month financing cash inflow was $115.979 million; investing cash outflow was $0.085 million. The positive operating cash flow included substantial noncash adjustments, including a $16.096 million debt-extinguishment loss.
- Profitability margins are not stated in the filing. For Q3, revenue was below operating expenses, resulting in an operating loss.
Material changes versus prior comparable periods
- Q3 revenue rose $0.040 million year over year, while operating expenses increased $1.049 million and the net loss narrowed by $1.250 million, largely because interest expense was lower and the fair-value adjustment was favorable.
- Nine-month revenue increased $15.146 million, primarily from two $10 million AZSTARYS-related regulatory milestone payments in 2021; the prior-year period included a $5 million NDA-acceptance milestone.
- Nine-month operating income improved by $12.966 million, but the company recorded a $16.096 million loss on debt extinguishment. The $60.194 million common-stockholder loss also includes $54.342 million in deemed dividends tied to warrant inducement transactions; these are not the same as cash operating losses.
- Cash increased from $4.213 million at December 31, 2020, to $131.503 million at September 30, 2021, primarily following equity offerings and warrant exercises. Common shares outstanding rose from 4.537 million to 35.317 million during that interval.
Outlook, commentary, and risks
- Management stated that existing cash resources were expected to fund operations for at least 12 months after the filing date. This estimate excluded projected revenue, including contingent royalties and milestones; the company cautioned that funding sufficiency and future proceeds were not guaranteed.
- No formal revenue or earnings guidance was provided. The filing listed anticipated Q4 2021 milestones of KP879 proof-of-concept data and a KP1077 pre-IND meeting; timing remained subject to uncertainty.
- The amended Commave agreement provides for up to $590 million in remaining AZSTARYS regulatory and U.S. sales milestones, plus tiered royalties. These amounts are contingent, not assured. Corium’s consulting agreement provides for quarterly payments through March 2022, with a further $2 million contingent on a milestone.
- A $75 million at-the-market equity facility was available, but no shares had been sold under it by September 30, 2021. Future equity issuance and outstanding warrants could dilute shareholders.
- Key risks include commercial adoption and reimbursement for AZSTARYS and APADAZ, dependence on partners, clinical and regulatory uncertainty for pipeline candidates, controlled-substance regulation, reliance on third-party manufacturers, potential need for additional capital, and possible effects of COVID-19.
- The company reported no material pending litigation expected to adversely affect its financial condition or results, and no accruals for commitments and contingencies. Management assessed disclosure controls as effective; no material change in internal control over financial reporting was reported.
- Subsequent to quarter-end, shares began trading on the Nasdaq Global Select Market on October 19, 2021.
Important facts for investors to verify
- Confirm the intended issuer: this source filing is for KemPharm, Inc., not Zevra Therapeutics, Inc.
- Review the Q3 commercial launch and subsequent AZSTARYS prescription, access, and reimbursement trends; the filing provides no sales-volume detail.
- Assess the timing and likelihood of future Commave milestones and royalties, Corium payments, and APADAZ-related receipts; none should be treated as assured revenue.
- Check cash use after quarter-end against management’s stated 12-month runway, including planned research and development spending and any additional financing.
- Evaluate potential dilution from outstanding warrants, equity compensation, and the unused $75 million ATM facility.